The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 144.40
Bid: 144.60
Ask: 145.00
Change: 0.00 (0.00%)
Spread: 0.40 (0.277%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 144.40
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Elementis Trading Update

28 Oct 2016 07:00

ELEMENTIS PLC - Elementis Trading Update

ELEMENTIS PLC - Elementis Trading Update

PR Newswire

London, October 27

28 October 2016

Elementis – Trading Update

Elementis plc (ELM.L, “Elementis” or the “Group”), the Global Specialty Chemicals Company, today issues a trading update for the three months ended 30 September 2016.

Commenting on the Group’s performance Chief Executive Officer, Paul Waterman, said:

“We continue to focus on prioritising our strategic agenda, which we will present in more detail at the Group’s Capital Markets Day presentation on 14 November 2016. I am pleased to report continued progress in Specialty Products and while trading conditions for Chromium continued to be challenging, overall Group earnings per share for 2016 are expected to be in line with market expectations.

Specialty Products’ performance in the period was positive, with strong growth in Personal Care and improved performance in Latin America coatings.

In Chromium, although the environment internationally remains challenging, contribution margins in North America and the rest of the world were stable. We continue to look at options to increase efficiency to help offset the competitive effects of a stronger dollar.

Cash generation continues to be an important component of the Group’s performance and, as previously stated, the net cash balance at the end of the year is likely to be higher than at the same time last year which, under our progressive dividend policy, will have a positive effect on the special dividend.”

Specialty Products’ sales were 6 per cent higher than in the same period last year on a constant currency basis, and 4 per cent on a reported basis. The remainder of this business commentary refers to constant currency sales.

In Coatings, Asia Pacific sales were 5 per cent ahead of the prior year as demand in China continued to reflect solid underlying growth. Sales in Latin America showed significant growth in the period, despite ongoing economic challenges in Brazil. The business benefited from new business wins at key accounts in Brazil, Mexico and Chile, which resulted in sales being 38 per cent higher than in the same period last year. Sales in North America were at a similar level to the comparator period, as overall demand continued to be negatively influenced by the impact of the strong dollar on North American exporters. In Europe, following a relatively strong second quarter (+4 per cent), sales in the period were 5 per cent lower than in the same period last year. We saw reduced consumption across Europe through our distributor channel whilst sales to Eastern Europe were also lower.

In Personal Care, where the Group has recently added more resources, sales were 38 per cent higher than in the same period last year. Excellent progress was made in growing sales of hectorite products in colour cosmetics and antiperspirants, while expanding sales geographically also showed good progress, particularly in Italy, China, India and Brazil.

In Oilfield Drilling, sales were 4 per cent lower than in the same period last year as demand patterns continued to remain relatively stable.

In Chromium, sales were 4 per cent lower than in the same period last year, on 3 per cent higher volumes, which was due to a continuation of the more challenging environment outside of North America, as reported in previous announcements. Compared to the second quarter, contribution margins in the period were relatively stable in North America and improved for sales outside of the region, as a result of a better product mix.

Consistent with the strategy to reduce activity in Surfactants over time, sales in the period were 14 per cent lower than in the same period last year and operating profit was consistent with the previously reported near break-even run rate in the first six months of the year.

The Group’s tax rate for the full year is expected to be lower than it was for the first six months of the year, due to changes in the geographic mix of profits, but overall Group earnings per share for 2016 are expected to be in line with market expectations. The Group’s balance sheet remains strong, with robust operating cash generation continuing to be a positive feature of the Group’s performance. Consequently, the Group’s year end net cash balance is expected to be higher than the $74 million reported at the end of 2015.

END

Enquiries
Elementis plc Paul Waterman, CEO Brian Taylorson, CFO Ralph Hewins, CFO-DesignateTel: +44 (0) 20 7067 2999
FTI Consulting Deborah Scott Matthew ColeTel: +44 (0) 20 3727 1000
Date   Source Headline
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSHalf-year Report
1st Aug 202211:08 amRNSTotal Voting Rights
21st Jul 20223:14 pmRNSHolding(s) in Company
1st Jul 20229:47 amRNSTotal Voting Rights
20th Jun 20221:54 pmRNSHolding(s) in Company
17th Jun 20224:35 pmRNSPrice Monitoring Extension
3rd May 202210:27 amRNSTotal Voting Rights
3rd May 20227:00 amRNSCompany Secretary Change
26th Apr 202212:28 pmRNSResult of AGM
26th Apr 20227:00 amRNSAGM Trading Statement
5th Apr 20224:17 pmRNSDirector/PDMR Shareholding
23rd Mar 20223:52 pmRNSAdditional Listing
22nd Mar 20224:18 pmRNSAnnual Financial Report & Notice of AGM
15th Mar 20227:53 amRNSDirectorate Change
8th Mar 202212:18 pmRNSDirector/PDMR Shareholding
8th Mar 202212:17 pmRNSDirector/PDMR Shareholding
8th Mar 202211:47 amRNSHolding(s) in Company
8th Mar 202210:43 amRNSDirector/PDMR Shareholding
8th Mar 202210:39 amRNSDirector/PDMR Shareholding
7th Mar 20223:26 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSPreliminary results year ended 31 December 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.